CDC data show cancer deaths declining as lung cancer treatment and detection advance, with new KRAS-targeted therapies showing early promise.
|Articles|September 14, 2021
Supplements and Featured Publications
- Strategies for Effective Cardiovascular Risk Management Through Lipid Management: A Transitional Approach From Hospital to Home
Strategies for Effective Cardiovascular Risk Management Through Lipid Management: A Transitional Approach From Hospital to Home
Advertisement
This publication was sponsored and written in partnership with Amgen.
On March 30, 2021, a group of cardiologists from leading medical centers across the United States and an executive leader representing a regional health plan convened for a virtual roundtable to discuss current challenges and effective strategies for advanced lipid management, including treatment options. This white paper captures actionable insights that were reported during the roundtable.
Advertisement
Related to this article
Nonadherence to semaglutide for obesity worsened once out-of-pocket costs passed roughly $75 per 30-day supply among commercially insured adults.
At a Stakeholder Interchange convened by The American Journal of Managed Care® in Houston, Texas, oncologists and pharmacists from academic and community practices debated how teclistamab- and talquetamab-based regimens stack up against CAR T-cell therapy in second-line multiple myeloma, and what it will take—staffing, caregiver support, hospital partnerships, and payer buy-in—to move step-up dosing out of the hospital and into the clinic.
All 50 states have applied for CMS's GENEROUS Model, a Medicaid drug pricing program expected to save $64.3 billion over the next decade.
HYPERION trial data shows a 76% reduction in clinical worsening events among adults recently diagnosed with PAH.
Diabetes care improves when support adapts to real-life changes, removing barriers and sustaining daily habits beyond reminders, education, and one-time interventions.
Imlunestrant plus abemaciclib doubled median PFS in patients with ESR1-mutated advanced breast cancer.
Global Burden of Disease data show prevalence fell nearly 30% from 1990 to 2021, yet the number of women affected grew 9.1%.
Advertisement
Advertisement